Atlas Trials

First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration

Clinical trial NCT07269665 · RECRUITING

Trial details

NCT number
NCT07269665
Sponsor
Axovia Therapeutics
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Bardet-Biedl Syndrome 1Retinal Degeneration
Start date
2026-06-26
Primary completion
2027-02-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.